Mary O’sUllivan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mary O’sUllivan has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Anne M. Talkington
Division of Pharmacokinetics, Pharmacodynamics, and Systems Pharmacology, Department of Pharmaceutical Sciences, University at Buffalo, SUNY, Buffalo, NY, USA; Institute for Artificial Intelligence and Data Science, University at Buffalo, SUNY, Buffalo, NY, USA
1 shared publication - Gabriel F. Hanson
Department of Biomedical Engineering, University of Virginia (UVA) School of Medicine, Charlottesville, USA
1 shared publication - Remziye E. Wessel
Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, USA
1 shared publication - Robert Weldon Barnes
Department of Biomedical Engineering, University of Virginia (UVA) School of Medicine, Charlottesville, USA
1 shared publication - Sepideh Dolatshahi
University of Virginia 1 Charlottesville, VA
1 shared publication - Shay Ladd
Department of Biomedical Engineering, University of Virginia (UVA) School of Medicine, Charlottesville, USA
1 shared publication
Latest Publications
- Open Access
- 8 September 2025
- Published by Springer Nature in Cellular and Molecular Bioengineering
- Vol. 18 (5) , 519-541
Uncovering Cellular Interactome Drivers of Immune Checkpoint Inhibitor Response in Advanced Melanoma Patients
Purpose: Despite the success of immune checkpoint inhibitors (ICIs) that target immunosuppressive interactions, treatment resistance remains a major clinical challenge. The tumor microenvironment is comprised of tumor, immune, and stromal cell types that communicate through secreted and cell surface proteins. This can be represented by a weighted, directed network where pairs of cell types communicate via multiple ligand-receptor interactions with varying strengths. Identifying interaction network motifs that are linked with outcome or evolve pre- to post-ICI presents a rational framework to identify combination therapeutic targets. Methods: Interaction inference was performed on publicly available single-cell RNA-sequencing data from melanoma patients. The constructed patient-specific networks were input to multivariate statistical learning approaches to identify network motifs that predicted response pre-treatment and that shifted pre- to post-treatment. Relevance of interactions was validated by (1) differential expression of related pathways in single cell RNA sequencing (scRNA-seq) data, (2) survival associations in an independent bulk RNA-seq dataset, and (3) repeated analyses of scRNA-seq data in a second cohort. Results: Immune-immune interactions with roles in T cell activation, chemotaxis, and adhesion were upregulated in patients who respond to therapy pre-treatment. Related pathways were perturbed in involved immune cells and expression of these genes was associated with improved survival. The interactome also distinguished pre- and post-treatment biopsies with high accuracy despite no significant differences in individual interactions. Analysis in the validation dataset with mixed responses pre-treatment recapitulated results from the discovery analyses. Conclusion: Unbiased analysis of interaction networks and their evolution is a powerful framework to guide prognostic indicators and novel combination targets to improve patient outcomes.
- 8 September 2025
- Published by Springer Nature in Cellular and Molecular Bioengineering
- Vol. 18 (5) , 519-541
Open AccessUncovering Cellular Interactome Drivers of Immune Checkpoint Inhibitor Response in Advanced Melanoma Patients
Purpose: Despite the success of immune checkpoint inhibitors (ICIs) that target immunosuppressive interactions, treatment resistance remains a major clinical challenge. The tumor microenvironment is comprised of tumor, immune, and stromal cell types that communicate through secreted and cell surface proteins. This can be represented by a weighted, directed network where pairs of cell types communicate via multiple ligand-receptor interactions with varying strengths. Identifying interaction network motifs that are linked with outcome or evolve pre- to post-ICI presents a rational framework to identify combination therapeutic targets. Methods: Interaction inference was performed on publicly available single-cell RNA-sequencing data from melanoma patients. The constructed patient-specific networks were input to multivariate statistical learning approaches to identify network motifs that predicted response pre-treatment and that shifted pre- to post-treatment. Relevance of interactions was validated by (1) differential expression of related pathways in single cell RNA sequencing (scRNA-seq) data, (2) survival associations in an independent bulk RNA-seq dataset, and (3) repeated analyses of scRNA-seq data in a second cohort. Results: Immune-immune interactions with roles in T cell activation, chemotaxis, and adhesion were upregulated in patients who respond to therapy pre-treatment. Related pathways were perturbed in involved immune cells and expression of these genes was associated with improved survival. The interactome also distinguished pre- and post-treatment biopsies with high accuracy despite no significant differences in individual interactions. Analysis in the validation dataset with mixed responses pre-treatment recapitulated results from the discovery analyses. Conclusion: Unbiased analysis of interaction networks and their evolution is a powerful framework to guide prognostic indicators and novel combination targets to improve patient outcomes.